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Abstract (132 words; 200 max)
The most severe clinical and pathologic manifestations of systemic sclerosis (SSc) are the
result of a fibrotic process characterized by the excessive and often progressive deposition of
collagen and other connective tissue macromolecules in skin and numerous internal organs. The
mechanisms involved in the initiation and progression of the remarkable fibrotic process in SSc
remain largely unknown. Extensive recent studies have indicated that a variety of polypeptide
growth factors play a crucial role in this process. The most commonly implicated growth factors
include transforming growth factor beta (TGF-β), connective tissue growth factor (CTGF),
platelet derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). Here,
the experimental evidence supporting the participation of various growth factors in the
pathogenesis of the fibrotic process in SSc and the molecular mechanisms involved will be
reviewed.
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(6,661 words)
The pathogenesis of Systemic Sclerosis (SSc) is complex and despite numerous studies
that have examined several aspects of its intricate picture, the exact mechanisms involved are not
well understood [1-4]. However, it is apparent that the most severe clinical and pathologic
manifestations of the disease are the result of a fibrotic process characterized by the excessive
and often progressive deposition of collagen and other connective tissue macromolecules in skin
and numerous internal organs. Tissue fibrosis in SSc is the result of an upregulated expression
of genes encoding collagen and other extracellular matrix proteins in affected organs. This is the
most important difference that distinguishes normal fibroblasts that promote normal wound
healing from SSc fibroblasts which display exaggerated and uncontrolled collagen and
extracellular matrix (ECM) production resulting in pathologic organ fibrosis [5-8].
The excessive collagen deposition in SSc is due to overproduction of this protein by an
expanded population of activated fibroblasts. Fibroblasts cultured in vitro from affected SSc
skin show characteristic features distinct from those of normal fibroblasts. SSc fibroblasts
appear to be very active in protein synthesis as demonstrated by the presence of distended and
enlarged rough endoplasmic reticulum, abundant cytoplasm, and numerous membrane-bound
vesicles containing proteinaceous amorphous material that most likely represent the exportation
of newly synthesized collagen and other ECM macromolecules into the extracellular space. The
exaggerated production of collagen and ECM proteins by SSc fibroblasts is maintained for serial
passages in vitro, suggesting that fundamental alterations in the regulation of collagen gene
expression have occurred in these cells [9,10].
A hallmark of the activation of fibroblasts is their conversion into myofibroblasts, a
process in which cells acquire the expression of smooth muscle actin and develop contractile and
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migratory properties [11]. In addition to their motile and contractile phenotype, myofibroblasts
display highly increased biosynthetic activity for collagen and other ECM proteins. The
transition into myofibroblasts involves a unique process of phenotypic transdifferentiation by
which quiescent fibroblasts, epithelial cells or endothelial cells/pericytes acquire myofibroblast
characteristics [12-14].
The origin of the overproducer fibroblasts in SSc has not been completely elucidated and
it is likely that several different pathways lead to the tissue expansion and accumulation of these
cells [15]. At least three distinct mechanisms of fibroblast expansion occurring in fibrotic
diseases have been identified. These include: (1) the activation of resident fibroblasts and the
selection of matrix overproducer and apoptosis resistant cells [16,17] through the effects of
cytokines and growth factors released from inflammatory cells infiltrating the affected tissue, (2)
the recruitment of circulating fibrocytes, a unique population of bone marrow derived
mesenchymal cell precursors characterized by the presence of both mesenchymal cell and bone
marrow origin markers [18-20] and (3) the transdifferentiation into myofibroblasts of either
epithelial cells or vascular cells such as pericytes or endothelial cells, in epithelial to
mesenchymal (EMT) or endothelial to mesenchymal transitions (EndoMT), respectively [12-14,
21-24].

Growth Factors
The mechanisms involved in the initiation and progression of the remarkable fibrotic
process in SSc remain largely unknown [1-4]. However, extensive recent studies have indicated
that a variety of polypeptide growth factors play a crucial role in this process. In the following
sections the experimental evidence supporting the participation of various growth factors in the
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pathogenesis of the fibrotic process in SSc and the molecular mechanisms involved will be
reviewed.
Transforming growth factor beta (TGF-β). TGF-β is a pleotropic growth factor that
plays crucial roles during embryogenesis, development of the immune system, malignant cell
transformation, vascular morphogenesis, inflammatory response, and wound healing, among
many others [25-27]. There are three isoforms of TGF-β which in addition to their primary
structure differ in their cellular origin, the kinetics of their expression, and their overall effects,
which are often organ specific and context-dependent. TGF-β1 is the most abundant isoform and
is most frequently implicated in the pathogenesis of various fibrotic processes including those
associated with SSc. TGF-β1 is produced by a large variety of cells, including fibroblasts and
macrophages, and most cells in the body have receptors for this isoform. TGF-β is initially
produced in a latent form in which the polypeptide is bound to a latency-associated peptide
(LAP) and is carried to the extracellular compartment as a large complex with a carrier protein,
latent TGF-β binding protein (LTBP). LTBP shuttles latent TGF-β to a storage compartment
comprised of ECM proteins such as elastin fibrils and fibronectin-rich pericellular matrices [2829]. Release of active TGF-β from the ECM storage sites requires either proteolytic cleavage,
which can be accomplished by numerous proteases including plasmin and certain matrix
metalloproteinases, or by conformational changes induced by interactions with thrombospondin
or certain integrins such as αvβ6 [30,31].
Canonical pathway of TGF-β signaling. Once activated, bioactive TGF-β in a dimeric
form binds to one of several transmembrane kinase receptors (TβR) and initiates a complex
series of intracellular reactions that transduce the signal from the cell surface to the nucleus and
eventually to the transcriptional regulatory elements of numerous TGF-β-responsive genes. The
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signaling events involve numerous intracellular molecules and pathways as illustrated in Fig. (1).
The classic pathway of TGF-β signal transduction involves the Smad family of intracellular
proteins [32-36] and is initiated by binding of dimeric TGF-β to the constitutively active
serine/threonine TβRII which recruits TβRI and then transphosphorylates it on three to five
serine and threonine residues in a short (30 amino acid) regulatory sequence known as the GS
region. TβRI is a member of a family of at least seven proteins known as activin receptor like
kinases (ALK). In fibroblastic cells the TβRI is ALK-5 whereas in endothelial cells it is ALK-1
although signaling through ALK-1 has also been observed in fibroblasts (see Fig (1)). The
phosphorylated TβRI receptor transduces the signal to the nucleus through the Smad family of
proteins. Smad2 or Smad3, two of the five receptor activated Smads (RSmads) then associate
with another protein, SARA, and become phosphorylated by the activated TβRI.
Phosphorylation allows these proteins to form a complex with the co-Smad, Smad4, which is a
cytoplasmic shuttle protein involved in the translocation of the Smad complex across the nuclear
membrane into the nucleus. Once in the nucleus, Smad3/Smad4 complexes act as transcription
factors by binding to specific DNA binding sites in the promoter regions of target genes and
thereby activating their expression [37]. In contrast, Smad2/Smad4 complexes do not appear to
directly bind to DNA promoter sites but instead exert their effect through their interactions with
other transcription factors or co-activator proteins. In addition to the ALK-5 initiated signaling,
it has been shown that in dermal fibroblasts important fibrogenic gene programs can also be
induced by ALK-1-mediated activation of Smad1 [38].
Fine tuning of TGF-β activity is achieved through a balance of positive and negative
effector molecules [39]. Of critical importance is the inhibitory Smad, Smad7, which inhibits
TGF-β signaling by binding to the type I receptor and thereby preventing recruitment and
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phosphorylation of RSmads [40,41]. Smad7 also facilitates TβRI ubiquitination by the Smurf
proteins by targeting the receptor for degradation, which leads to inhibition of RSmad activation
[42]. Other mechanisms of fine regulation include dephosphorylation of Smads through specific
phosphatases as well as regulation of Smad nucleocytoplasmic shuttling and nuclear trapping.
Non-canonical pathways of TGF-β signaling. Numerous studies have shown that
important TGF-β functions are mediated by protein cascades that are independent of
Smad2/Smad3 signaling and that these pathways may become activated in a cell-specific and
context-dependent manner [43-45]. These non-Smad pathways involve a variety of other proteins
such as, for example, the non-receptor tyrosine kinase cytoplasmic Abelson kinase (c-Abl),
protein kinase C-δ (PKC-δ), phosphoinositol 3 kinase (PI3K), and Akt/PKB as shown in Fig. (1).
Numerous recent studies have demonstrated the involvement of non-Smad pathways in the
development of tissue fibrosis in SSc and have suggested that pharmacologic interventions
directed at the blockade of one or more components of these pathways may prove to be effective
therapeutic approaches for the disease.
Cytoplasmic Abelson kinase (c-Abl). c-Abl is a non-receptor tyrosine kinase implicated
in numerous intracellular transduction pathways including cell differentiation, cell division, cell
adhesion, and stress responses.

Translocation of the genomic region containing the gene

encoding c-Abl from chromosome 9 to chromosome 22 is responsible for the development of
chronic myelogenous leukemia [46,47]. A recent review discussed numerous recent studies
showing that activation of c-Abl induced by TGF-β is likely to contribute to the fibrosis and
vasculopathy of the skin and internal organs in SSc [48]. One additional mechanism involving
the c-Abl kinase has been implicated in the development of fibrosis in SSc. This study focused
on the activation of Smad1 in SSc and found that that levels of phosphorylated Smad1 were
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found to be significantly elevated in SSc skin biopsy samples and in cultured SSc fibroblasts.
The potent tyrosine kinase inhibitor, imatinib mesylate, blocked activation of the Smad1 pathway
in TGF-β stimulated control fibroblasts and reversed activation of this pathway in SSc
fibroblasts. These findings demonstrated that activation of Smad1 signaling contributes to the
persistent activation of SSc fibroblasts and that this pathway is blocked by imatinib mesylate
[49]. The role of c-Abl as an important mediator of tissue fibrosis in SSc has been further
supported by numerous studies in vitro in cultured fibroblasts as well as in animal models of SSc
and fibrosis, and by numerous reports of uncontrolled clinical studies describing SSc patients
who experienced improvement in cutaneous sclerosis in response to imatinib mesylate therapy
[50-53].
PI3K/Akt Pathways. Critically important pathways are initiated by TGF-β activation of
phosphoinositide 3-kinases (PI3Ks), which phosphorylate inositol-containing lipids to yield
phosphoinositol 3 phosphate (PIP3) [54]. PIP3 then recruits the phosphoinositide-dependent
kinase (PDK)-1 and Akt/protein kinase B (PKB), bringing these proteins into proximity at the
plasma membrane where Akt/PKB is phosphorylated by PDK-1 [55]. Once activated, Akt leaves
the plasma membrane to phosphorylate intracellular substrates and also translocates to the
nucleus where it can phosphorylate and activate transcription factors. Studies in several cell
systems, including human mesangial cells and lung and dermal fibroblasts, suggest that Akt may
have dual profibrotic effects, increasing collagen synthesis and decreasing its degradation via
downregulation of matrix metalloproteinase 1, and several studies have shown that specific Akt
inhibition may have a potent antifibrotic effect [56]. Furthermore, Akt/PKB may participate in
EMT induction through phosphorylation of GSK-3 and also increase cell proliferation and
survival through its inhibition of apoptotic pathways. The potential role of PI3K and Akt/PKB in
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the pathogenesis of tissue fibrosis in SSc has been supported by studies which showed enhanced
activation of Akt in SSc fibroblasts [57] and elevated activity of PI3K and Akt/PKB in platelets
from patients with SSc [58].
Protein kinase C-δ (PKC-δ). PKC-δ is a serine- and threonine-specific protein kinase
involved in cell signaling and in the regulation of growth, apoptosis, and differentiation of a
variety of cell types. Several studies examined the role of PKC-δ in the pathogenesis of fibrotic
diseases including SSc. Fibroblasts from patients with SSc were shown to contain higher PKC-δ
levels than normal cells and further studies demonstrated that PKC-δ was capable of inducing a
potent stimulation of collagen gene expression.

PKC-δ inhibition with the highly specific

inhibitor, rottlerin, or by expression of a dominant-negative PKC-δ construct reduced type I
collagen production and abrogated TGF-β stimulation of collagen gene expression in human
fibroblasts [59]. Other studies examined the role of PKC-δ on the repression of TGF-β activity
and focused on the transcription factor Fli1 (Friend leukemia integration-1) [60,61]. Fli1 binds
directly to the α2 type I human collagen gene promoter, inhibiting its transcription. Fli1
reduction increased TGF-β-dependent profibrotic gene expression, whereas increased Fli1
expression blocked these effects. Study of the mechanisms responsible indicated that TGF-β
induces phosphorylation of PKC-δ which in turn phosphorylates Fli1. This step is essential for
Fli1 release from the collagen gene promoter with the resulting removal of its inhibitory
influence and a consequent increase in the α2(I) collagen gene transcriptional activity. These
observations confirmed earlier studies demonstrating that inhibition of PKC-δ by pharmacologic
or molecular biologic techniques diminished the expression of types I and III collagens induced
by TGF-β as well as the increased expression of these genes by cultured SSc fibroblasts [59,60].
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Caveolin-1 regulation of TGF-β signaling. Another recently identified mechanism of
regulation and fine tuning of TGF-β activity involves caveolin-1.

Caveolin-1, the most

important member of a family of proteins found in lipid rafts, plays an important role in TGF-β
signaling regulation owing to its participation in TβR internalization as illustrated in Fig. (2).
TβR are internalized both by caveolin-1 associated lipid rafts and by early endosome antigen 1
(EEA-1) non-lipid raft pathways. It has been shown, furthermore, that non-lipid raft associated
internalization increases TGF-β signaling, whereas, caveolin-associated internalization increases
TβR degradation, thereby effectively decreasing or abolishing TGF-β signaling [62].
Specifically, it was demonstrated that SARA and Smurf, upstream regulators of either TGF-β
signaling or TβR degradation, respectively, were localized in distinct subcellular compartments.
The complex SARA/Smad2/3 which initiates TβR-1 signaling was found to be localized in a
non-lipid raft EEA-1 positive compartment, whereas the Smurf/Smad7 complex responsible for
initiating proteasome degradation of TβRs was found to be localized in caveolin-1 positive lipid
rafts. The localization of the TβRs in the EEA-1 positive compartment was responsible for
downstream Smad activation, whereas their localization in caveolae lipid rafts caused
recruitment of Smurf/Smad7 with subsequent receptor ubiquitination and rapid receptor
degradation and turnover [63,64].
This novel mechanism of regulation of TβR function and activity follows ligand
engagement and is dependent on the fluidity of the membrane and the membrane density of the
distinct caveolin-1 and non-caveolin compartments.

Thus, absence of one compartment or

imbalance in the densities of the two compartments may affect the level of TGF-β pathway
activity given the same amount of ligand binding. Furthermore, since this process occurs at the
level of internalization of the TβR immediately following ligand engagement, it likely represents
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an important mechanism of regulation of TGF-β signaling. Thus, a reduction of caveolin-1
would result in uncontrolled activation of all TGF-β mediated pathways including those
responsible for tissue fibrosis.

One unique feature of this regulation mechanism is that it

provides a cogent and plausible mechanism for the perpetuation of tissue fibrosis following an
initial triggering event. The triggering event results in a decrease in caveolin-1 gene expression;
this decrease then shifts TGF-β internalization through the EEA-1 pathway, leading to
accentuation of the TGF-β-induced fibrotic effects and simultaneously causing further
downregulation of caveolin-1 gene expression.

Thus, the current evidence indicates that

caveolin-1 is a crucial regulator of TGF-β intracellular signaling and TβR endosomal
degradation and, therefore, may play a key role in the pathogenesis of disorders characterized by
exaggerated tissue fibrosis.
Numerous studies have supported this role of caveolin-1 in the development of tissue
fibrosis [65-68]. For example, it was shown that caveolin-1 knockdown in vitro markedly
increased collagen gene expression in normal human lung fibroblasts and that caveolin-1 was
reduced in affected SSc lungs and skin [66] and in lung tissues and fibroblasts from patients with
idiopathic pulmonary fibrosis [67,68]. Increasing caveolin-1 expression markedly improved
bleomycin-induced pulmonary fibrosis [67]. Furthermore, restoration of caveolin function
employing cell permeable peptides abrogated TGF-β activation of cultured human dermal
fibroblasts, and it was suggested that restoration of caveolin function employing the active
caveolin-1 scaffolding domain coupled to cell-permeable carrier peptides may represent a novel
approach for treatment of fibrotic diseases including SSc [65,66].
Roles of TGF-β in SSc-associated tissue fibrosis. Numerous studies have shown that
alterations in TGF-β signaling are involved in the pathogenesis of diverse human diseases [69-
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72]. However, owing to its multiple and potent profibrotic effects, TGF-β has been considered
one of the key molecules involved in the pathogenesis of a variety of fibrotic diseases as well as
in SSc tissue fibrosis [1-4,73-77].

One of the most important effects of TGF-β1 is the

stimulation of the synthesis of a variety of ECM macromolecules by fibroblasts and other
mesenchymal cells as evidenced by a remarkable increase in response to TGF-β treatment of the
production of collagens type I, III, V, and VI, fibronectin and α-smooth muscle actin (α-SMA), a
molecular marker of activated myofibroblasts [78-83]. TGF-β1 also decreases the synthesis of
collagen-degrading metalloproteinases and stimulates the production of protease inhibitors such
as tissue inhibitor of metalloproteinases 1 (TIMP-1) [84,85]. Small amounts of TGF-β sensitize
fibroblasts to its own effects and maintain them in a persistently activated state involving an
autocrine mechanism that causes further production of TGF-β [86]. It has also been shown that
SSc fibroblasts express increased numbers of TGF-β receptors on their surface and display
altered ratios of these receptors, alterations that have been suggested to account for the increased
TGF-β–induced signaling and the resulting stimulation of collagen production in these cells [87].
Another important profibrotic effect of TGF-β is the induction of epithelial-mesenchymal
transition [12-14,88,89] and although less extensively studied, it also appears that TGF-β might
induce a similar transdifferentiation process in endothelial cells [22-24]. Another important
effect of TGF-β is the potent downregulation of caveolin-1 expression resulting in a marked
reduction of its protein levels. As discussed above and illustrated in Fig. (2), a reduction in
caveolin-1 would allow the uncontrolled and persistent activation of TGF-β mediated pathways.
A large number of studies have examined various aspects of the complex TGF-β pathway
to determine the role of this growth factor in SSc pathogenesis. The various steps of TGF-β
signaling including the extracellular processing and the intricate intracellular signaling pathways
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involved in the TGF-β pleotropic effects have been extensively examined in SSc fibroblasts and
tissues. The circulating levels of active TGF-β1 were measured in a cross-sectional study of
diffuse or limited SSc in comparison with healthy controls. No significant differences were
found in the levels of total serum TGF-β1. However, patients with diffuse SSc consistently
displayed lower levels of active TGF-β1 than patients with limited SSc or normal individuals.
The reduction in TGF-β1 correlated with recent onset and more extensive skin sclerosis,
suggesting that active TGF-β1 may be sequestered in actively involved SSc skin [90].
Several studies examined the spontaneous production of active and total (active plus
latent) TGF-β1 by cells from SSc patients. One study examined the production of TGF-β from
peripheral blood mononuclear cells (PBMC). Greater amounts of both latent and active TGF-β
were produced by PBMC from SSc patients than those from normal subjects in autologous
mixed lymphocyte reaction assays [91]. Another study showed that PBMC from patients with
limited or diffuse cutaneous SSc had significantly elevated values compared to PBMC from
normal controls. Furthermore, PBMC from patients with disease of recent onset displayed
increased production of active or total TGF-β1 compared to patients with disease of less recent
onset. However, although the production of active TGF-β1 by PBMC from patients with diffuse
SSc was higher compared with PBMC form patients with limited SSc, the differences were not
statistically significant. Analysis of leukocyte subsets showed that the spontaneous production of
total

TGF-β1

in

SSc

patients

was

significantly

higher

in

cultured

peripheral

monocytes/macrophages, but not in T cells, B cells, or NK cells [92]. In subsequent studies, the
production of active and total TGF-β1 levels by cultured dermal fibroblasts was measured. SSc
fibroblasts expressed increased levels of TGF-β type I and type II receptors but the secreted
amounts of TGF-β were similar to those secreted by normal fibroblasts [93].
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The initial step in activation of the TGF-β signaling pathway involves the release of the
active polypeptide from its sequestered precursor bound in a latent state to ECM proteins. One
of the novel mechanisms involved in this process was recently shown to require the induction of
conformational changes in the protein by αvβ5 integrin [31]. Therefore it was of interest to
examine the levels of this integrin in SSc. In one study, levels of αvβ5 expression were found to
be significantly elevated in SSc fibroblasts compared with normal fibroblasts, and treatment of
these cells with anti-αvβ5 antibody or β5 antisense oligonucleotide significantly blocked the
TGF-β pathway causing reduced collagen gene promoter activity and reversal of the
myofibroblastic features of SSc fibroblasts. These results indicated that upregulated expression
of αvβ5 integrin contributes to the establishment of autocrine TGF-β signaling in SSc fibroblasts
through activation of endogenous latent TGF-β1 [94].
Following release of active TGF-β from its ECM storage sites, a dimeric form of the
polypeptide engages the corresponding cellular membrane receptor. Studies of the expression
levels of TGF-β receptors in SSc skin biopsies using in situ hybridization and
immunohistochemical analysis showed that the expression levels of both TβRI and TβRII were
elevated in the dermal fibroblasts of SSc skin sections in comparison to normal skin sections, and
the numbers of fibroblasts expressing these TβR were increased in the SSc skin sections
compared to normal controls. These results suggested that an autocrine TGF-β signaling due to
the overexpression of TβRI and TβRII in dermal fibroblasts is involved in the pathogenesis of
dermal fibrosis in patients with SSc [95].
In fibroblasts, TGF-β signaling occurs primarily through the ALK-5 type I TβR receptor
which triggers the canonical Smad signaling pathway. Accordingly, numerous studies have
examined these early steps of the TGF-β signaling cascade.
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SB431542, a small-molecule inhibitor of ALK-5, were examined in cultured fibroblasts and it
was shown that SB431542 abrogated TGF-β-induced phosphorylation and nuclear transport of
endogenous Smad2/3 and Smad4 and it inhibited TGF-β-induced stimulation of collagen,
fibronectin, and connective tissue growth factor gene expression. The ALK-5 inhibitor also
abolished TGF-β autoinduction and myofibroblast transdifferentiation [96]. In a related study,
the effect of the ALK-5 inhibitor SD208 on the expression of key biochemical markers of the
fibrotic phenotype was compared in SSc fibroblasts and in normal fibroblasts. Inhibition of
ALK-5 reduced the expression of a cohort of fibrotic markers by SSc dermal fibroblasts,
including type I collagen and β1 integrin, and attenuated the elevated adhesive and contractile
properties of SSc fibroblasts indicating that some of the key profibrotic features of SSc
fibroblasts are dependent upon ALK-5 activity [97].
A large number of studies exploring the intracellular steps of TGF-β signal transduction
in SSc cells have been reported. In particular, the role of Smad proteins in the pathogenesis of
tissue fibrosis in SSc has been studied extensively and it has become apparent that the complex
pathway involving intracellular Smad proteins is of crucial importance in the regulation of the
fibrotic response in SSc [36,98-100]. One study examined the expression levels of Smad2,
Smad3 and Smad4, as well as Smad3 phosphorylation in parallel with an assessment of the
transcriptional activity of collagen genes in SSc cultured fibroblasts. Increased Smad3
phosphorylation and increased collagen gene transcriptional activity were found in SSc
fibroblasts compared with normal fibroblasts. The induced overexpression of Smad3 caused a
potent increase in collagen gene promoter activity in normal fibroblasts. These results
demonstrated an important role of the Smad3 activation of the canonical TGF-β signaling
pathway in the stimulation of collagen gene transcriptional activity in SSc fibroblasts [101].
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To further characterize the mechanism of regulation of collagen gene expression in SSc
and healthy skin fibroblasts the roles in TGF-β signaling of the p38 mitogen-activated protein
kinase (MAPK) which is an important regulator of stress responses and apoptosis, and of the coactivator histone acetyl transferase p300, which regulates cell differentiation, were examined. In
the studies of p38, treatment of dermal fibroblasts with TGF-β resulted in a prolonged activation
of this kinase. Furthermore, a specific inhibitor of p38 suppressed TGF-β stimulation of collagen
type I mRNA and the α2(I) collagen promoter activity, whereas ectopic expression of p38α
enhanced the promoter activity of the collagen gene and potentiated TGF-β stimulation of this
promoter. However, both cell types exhibited similar total levels of p38 MAPK and similar
kinetics of p38 activation in response to TGF-β suggesting that the p38 MAPK pathway is not
dysregulated in SSc fibroblasts [102]. In the studies with p300 it was shown that TGF-β induced
an increase in p300 levels in normal fibroblasts and that forced expression of p300 dramatically
enhanced the magnitude of TGF-β responses. Furthermore, TGF-β lost its ability to induce
Smad-dependent transcription in p300-depleted fibroblasts. These responses could be fully
rescued with ectopic p300. Levels of p300 were higher in cultured fibroblasts derived from SSc
patients than in fibroblasts from matched normal controls. These results established conclusively
that p300 is an essential component of the cellular TGF-β signal transduction pathways
mediating stimulation of collagen synthesis in fibroblasts and may, therefore, be an important
contributor to the progression of skin fibrosis in SSc and may represent a novel therapeutic target
[103].
TGF-β microarray/Analysis of global gene expression and SSc pathogenesis. The
recent development of high throughput genomic profiling technologies such as cDNA
microarrays, combined with advanced computational approaches, allow the identification and
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characterization of high-resolution expression profiles of numerous disease states, the detailed
analysis of molecular networks that underlie specific disease phenotypes and the discovery of
novel targets for therapeutic intervention.
Global gene expression studies have advanced substantially current understanding of SSc
pathogenesis and will very likely provide molecular signatures that may allow the identification
of SSc patients who may respond and benefit from specific therapies. One such study employed
genome-wide gene expression microarrays to identify the pattern of TGF-β-responsive genes in
SSc fibroblasts. The TGF-β-responsive signature comprising 674 uniquely expressed genes was
present in about 60% of diffuse SSc skin biopsies, but was not found in limited SSc, morphea, or
healthy control biopsies. The clinical subset of the TGF-β-responsive signature patients showed
more severe skin involvement and a higher likelihood of scleroderma lung disease and is more
likely to derive clinical benefit form anti-TGF-β therapeutic approaches [104].
Connective tissue growth factor (CTGF). CTGF, also known as CCN2, is another
pleotropic growth factor that has recently emerged as an important mediator of normal and
pathological tissue fibrotic responses [105-107] and has been suggested to play a crucial role in
SSc tissue fibrosis [108-110]. CTGF was originally identified in human umbilical vein
endothelial cells, and previous studies revealed that human skin fibroblasts produce CTGF
following stimulation with TGF-β [105]. In addition to a potent profibrotic effect, CTGF
participates in angiogenesis, axial development of the musculoskeletal system, structural
organization of connective tissues, and embryo implantation. TGF-β stimulates CTGF synthesis
in fibroblasts, vascular smooth muscle cells and endothelial cells, and numerous studies have
shown that it represents a downstream mediator of TGF-β fibrogenic effects. Indeed, the CTGF
produced by these cells in response to TGF-β stimulation in turn stimulates the synthesis of such

17

convertdoc.input.557475.l9K2M
9:32:05 PM

ECM components as type I collagen and fibronectin in dermal and lung fibroblasts and very
likely also in endothelial cells. These observations prompted a large number of studies
examining the role of CTGF in the pathogenesis of SSc [108-110]. A study to determine the
clinical correlation of CTGF serum levels in patients with SSc showed that SSc patients with
elevated CTGF had disease of more recent onset and of greater severity, including the more
frequent development of pulmonary fibrosis with decreased DLCO and decreased vital capacity.
Thus, serum CTGF levels were increased in patients with more severe SSc and correlated with
the extent of skin sclerosis and the severity of pulmonary fibrosis [111]. Another study assessed
CTGF expression in SSc tissues and found strong CTGF signals in fibroblasts of affected skin
from patients with SSc, whereas there was no expression in the skin from normal controls [112].
CTGF has also been found to be overexpressed in lung fibroblasts isolated from SSc patients. A
recent study examined CTGF induced changes in the lung fibroblast proteome and identified
novel CTGF-responsive molecules that may play important roles in pulmonary fibrosis. One of
these novel CTGF-induced proteins, IQ motif containing GTPase activating protein (IQGAP) 1,
was found to be elevated in lung fibroblasts isolated from SSc patients with pulmonary fibrosis.
Depletion of IQGAP1 expression by small interfering RNA inhibited CTGF-induced cellular
migration. These findings further implicate the importance of CTGF in lung tissue repair and
fibrosis [113].
Platelet-derived growth factor (PDGF). Members of the PDGF family, which is
comprised of four different polypeptides (PDGF-A, B, C, and D) that form disulfide-bonded
dimers (PDGF-AA, BB, CC, DD, and AB), play an important role during embryonic
development and contribute to the maintenance of connective tissue in adults. PDGF are potent
mitogens and chemoattractants for a variety of inflammatory and mesenchymal cells, in
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particular, for vascular smooth muscle cells [114]. PDGF effects are mediated by a complex
cascade initiated by activation of two distinct receptor tyrosine kinases (PDGFRα and β) that
drive a potent mitogenic stimulation of vascular smooth muscle cells and dermal fibroblasts
[115]. Dysregulation of PDGF signaling has been linked to numerous disorders including
atherosclerosis and pulmonary hypertension [116,117]. PDGF has also been implicated in the
pathogenesis of numerous fibroproliferative diseases, including SSc [118-119].

Elevated

expression of PDGF and its receptors has been found in SSc skin and lung tissues and there is
evidence that TGF-β stimulates the expression of PDGFRα in SSc cells and increases their
response to PDGF, suggesting that cross-talk between TGF-β and PDGF pathways may regulate
chronic fibrosis in SSc [120].
To examine the role of PDGF and TGF-β in the pathogenesis of SSc-associated
pulmonary fibrosis, PDGF and TGF-β levels were determined in bronchoalveolar lavage (BAL)
fluid from patients with SSc and healthy controls. BAL fluid from SSc patients was found to
contain significantly elevated levels of PDGF-AA, PDGF-BB, and TGF-β1 [121]. SSc lung
myofibroblasts pretreated with TGF-β 1 exhibited an enhanced mitogenic effect upon stimulation
by PDGF, caused in part by the induction of the PDGFα receptor. These studies support a role
for PDGF and TGF-β 1 in the pathogenesis of SSc lung disease. The potent smooth muscle cell
mitogenic effects of PDGF have been implicated in the severe fibroproliferative changes in the
pulmonary vasculature occurring during the development of primary pulmonary hypertension
[122] and it has been suggested that highly selective tyrosine kinase inhibitors such as imatinib
and dasatinib that are capable of abrogating the activation of PDGF receptor tyrosine kinase may
be effective therapies for primary pulmonary hypertension and provides support for their use in
the treatment of SSc [119,122-124].
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Of substantial interest has been the recent description of the occurrence in the sera of SSc
patients of functional anti-PDGF receptor-specific autoantibodies capable of activating and
initiating PDGF signaling [125]. In this study, stimulatory antibodies to the PDGFR that were
capable of activating collagen-gene expression and inducing the production of reactive oxygen
radicals (ROS) in mouse-embryo fibroblasts were found in all the SSc patients studied. The
antibodies recognized native PDGFR, inducing tyrosine phosphorylation and ROS accumulation
and stimulation of type I collagen-gene expression as well as myofibroblast phenotype
conversion in normal human primary fibroblasts. These results suggested that functional antiPDGF antibodies have a causal role in the pathogenesis of SSc [126]. Given the potential
importance and significance of these results, several subsequent studies were performed to
confirm the presence of functional anti-PDGFR antibodies in patients with SSc. In one study,
immunoglobulins (IgGs) from 37 patients with SSc were purified and PDGFR activation tested
using 4 different bioassays. Purified IgG samples from patients with SSc were positive when
tested for antinuclear autoantibodies, but failed to specifically activate PDGFRα or PDGFRβ in
any of the tests [127]. Another study employed an electrochemiluminescence binding assay for
detection of serum autoantibodies to PDGFRα, PDGFRβ, epidermal growth factor receptor
(EGFR), and colony-stimulating factor receptor 1 (CSFR1), and the level of receptor
phosphorylation induced by pure Ig was determined by enzyme-linked immunoassay, Western
blot, and functional agonist activity mitogenic assay. Although approximately one-third of sera
samples from SSc patients contained detectable autoantibodies to PDGFR, these antibodies were
not specific to SSc, since they were also detected in a similar percentage of samples from normal
subjects. Furthermore, PDGFRα agonist activity was not demonstrated when purified IgG from
these sera was tested in cell-based assays [128]. A third study to evaluate the presence of anti-
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PDGFRα antibodies in patients with SSc found non-significant differences between patients with
SSc and controls and there was no correlation between the presence or titers of anti-PDGFRα
antibodies and the clinical and serological features of SSc. Furthermore, serum samples from
patients with SSc and healthy people recognized the same band corresponding to PDGFRα by
immunoblot [129].

Thus, the current evidence is not conclusive and there is substantial

controversy and uncertainty about the presence of functional PDGFRα activating antibodies in
the sera of SSc patients.
Fibroblast growth factors (FGF). FGF comprise a large family of growth factors which
play a crucial role during embryonic development, participating in numerous differentiation
processes including mesoderm induction and mesenchymal-epithelial signaling [130,131]. FGF
are potent mitogenic factors that have numerous functions in adult organisms such as
angiogenesis and wound healing [132]. FGF are secreted glycoproteins produced by a variety of
cells which, following secretion, are stored in the extracellular compartment by binding to
heparan sulfate proteoglycans. FGF signaling occurs through 4 distinct transmembrane receptor
kinases and complex cascades of intracellular reactions that lead to activation or repression of the
expression of numerous target genes [133]. Numerous studies have demonstrated the potent
fibroblast mitogenic effects of FGF during inflammatory and fibrotic responses. However, the
marked increase in cellular proliferation is accompanied by a reduction in expression of collagen
and other ECM molecules. Thus, the role of FGF in the pathogenesis of SSc tissue fibrosis is not
fully understood.
One recent study examined basic FGF (bFGF) expression in skin biopsies from SSc
patients and found increased expression in the epidermis and dermis as compared to normal
tissues. However, there was no correlation of the levels of expression with the duration of
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disease or the extent of skin involvement, although some of the results suggested that bFGF may
act in an autocrine or paracrine manner in fibrogenesis [134]. In contrast, another study showed
that bFGF is a potent inhibitor of basal and TGF-β stimulated collagen expression in human
fibroblasts, and that this effect was no different in SSc than in healthy fibroblasts [135].
Therefore, the role of FGF in the initiation of progression of the fibrotic process in SSc has not
been completely elucidated and additional studies will be required to conclusively determine the
contribution of this potent growth factor to the pathogenesis of fibrosis in SSc.
Vascular endothelial growth factor (VEGF). VEGF is an endothelial cell specific
growth factor with multiple functions including stimulation of endothelial cell proliferation and
differentiation, modulation of endothelial permeability, and potent effects on vascular
remodeling [136]. Expression of VEGF is markedly induced by hypoxia and is regulated by
hypoxia-inducible factor 1α. A recent study suggested that tissue hypoxia in affected skin and
other organs of patients with SSc may result in alterations in VEGF regulation and therefore may
play an important role in the altered angiogenesis which is a characteristic feature in SSc [137].
Measurement of serum levels of VEGF in patients with SSc and healthy controls showed
that serum VEGF levels were significantly higher in SSc patients and correlated well with the
extent of skin sclerosis. Serum VEGF levels were also inversely correlated with nailfold
capillary density, suggesting that high VEGF levels may participate in the capillary damage in
SSc [138]. In another study, serum levels of VEGF were measured in patients with various
connective tissue diseases. Patients with diffuse SSc showed elevated VEGF levels in
comparison with normal controls. An elevated serum VEGF level was correlated with the
frequency of lung fibrosis and reduced vital capacity in the patients with SSc [139]. However,
although serum VEGF levels were found to be consistently elevated in SSc patients, the source
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of circulating VEGF was not known. In one study the role of platelets as a source of VEGF and
other angiogenic mediators of SSc was examined. The results showed that platelets from SSc
patients, in contrast to controls, secreted large amounts of VEGF and suggested that these cells
may play an important role in the altered angiogenesis associated with the disease through the
secretion of high levels of VEGF [140]. Given the potent proangiogenic effects of VEGF, the
role of this growth factor in the pathogenesis of SSc associated fibroproliferative alterations such
as pulmonary artery hypertension (PAH) has been the subject of intense investigation. An
evaluation of the relationships between pulmonary artery pressure, clinical and functional
manifestations of SSc and serum VEGF levels showed that serum VEGF levels were increased
in SSc patients with PAH and suggested a possible role of VEGF in the pathogenesis of PAH in
SSc [141].
It has been proposed that the disturbed vessel morphology with enlarged capillaries and
an overall reduction in capillary density frequently present in SSc may represent an insufficient
angiogenic response and that these abnormalities may be due to reduced VEGF expression.
However, in refutation of this hypothesis was the observation that the expression of both VEGF
and its receptors VEGFR-1 and VEGFR-2 were upregulated in SSc skin. Upregulation of VEGF
was likely mediated by an altered expression pattern of various cytokines [142]. Thus, these
results do not support the notion that alterations in VEGF signaling are responsible for the
occurrence of capillary abnormalities in SSc.
Insulin-like growth factor (IGF) and insulin-like growth factor binding proteins
(IGFBP). IGFs comprise a family of regulatory polypeptides with high sequence similarity to
insulin that are involved in numerous physiologic states including growth and development,
cellular proliferation and apoptosis, and aging [143,144]. IGFs are part of a complex protein
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network comprising two distinct IGF molecular species (IGF-1 and IGF-2), two cell surface
receptors (IGFR1 and IGFR2), and six specific binding proteins (IGFBP1-6). The IGFBPs
modulate the function of IGFs by sequestering them with high affinity within the extracellular
matrix [145]. Several studies have examined the role of IGFs and IGFBPs in fibrotic conditions
including pulmonary fibrosis and SSc.

Stimulation of fibroblast proliferation induced by

bronchoalveolar lavage from patients with SSc associated pulmonary fibrosis was found to be
caused largely by IGF-1 as demonstrated by inhibition with specific antibodies [146].
Supporting the profibrotic role of IGFBP, elevated levels of IGFBP-3 and -5 were found in
pulmonary fibrosis [147]. Furthermore, measurements of serum IGF-1 and IGFBP-3 levels in
patients with SSc were found to be significantly elevated compared with patients with systemic
lupus erythematosus or healthy controls. IGF-1 levels correlated with the extent of skin
involvement and the presence of pulmonary fibrosis.

Furthermore, IGF-1 mRNA was

upregulated in the affected skin of patients with SSc. These results collectively suggested that
IGF-1 and IGFBP-3 are involved in the development of fibrosis in SSc [148].
In another study, IGF-2 expression was examined in explanted lung tissues from control
and SSc patients to determine its role in the pathogenesis of SSc associated pulmonary fibrosis.
Immunostaining revealed increased IGF-2 expression in fibroblastic foci of SSc lungs and
cultured primary SSc lung fibroblasts had a fourfold increase in IGF-2 mRNA and a twofold
increase in IGF-2 protein compared with normal lung fibroblasts. IGF-2 induced a dose- and
time-dependent increase in collagen type I and fibronectin production and triggered the
activation of several important kinase pathways including the PI3K signaling cascade. These
results provided strong support and novel insights into the role of IGF-2 in the pathogenesis of
SSc-associated pulmonary fibrosis [149].
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Concluding Remarks
Remarkable recent progress in the understanding of the molecular events involved in the
development of SSc tissue fibrosis has allowed the identification of key molecules, key cellular
mechanisms, and key intracellular signaling cascades that mediate the initiation and progression
of fibrosis in this disorder. Results of these studies have provided novel approaches for the
treatment and correction of the molecular alterations involved in the fibrotic component of SSc,
among which the most promising appear to include modifiers

of TGF-β1 activation and

signaling, tyrosine kinase inhibitors, and inhibitors of other growth factors involved in the
fibrotic process [48,51,150].

Many of these approaches have already been confirmed by

extensive clinical and preclinical evidence and it is likely that they will be available for clinical
use in the near future. Furthermore, it is expected that given the strong molecular rationale for
their use these novel therapies will be highly effective in controlling and reversing the severe
clinical manifestations of the fibrotic process in SSc.
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1.

Figure Legends

Figure 1. Transforming growth factor beta (TGF-β) signaling pathways critical for the
fibrotic response. Illustrated are several profibrotic pathways initiated by TGF-β binding in
fibroblastic cells. Following TGF-β binding, the TβRII receptor recruits either ALK-1 or ALK-5
type I receptor (TβRI) and activates it by phosphorylation.

ALK-5 then specifically

phosphorylates receptor-regulated Smad-2 and Smad-3 whereas ALK-1 phosphorylates Smad-1.
The receptor Smads, Smad2 or Smad3, then complex with Co-Smad-4 resulting in their
transport to the nucleus where they regulate transcription of critical genes, here represented by
CTGF, α1(I) , and α2(I) collagen. Also illustrated are three non-Smad pathways (c-Abl , PKC-δ
and Akt/PKB). One of the two PI3K pathways activates c-Abl, whereas the other activates
Akt/PKB, an important mediator participating in myofibroblast differentiation through EMT as
well as through increasing cellular proliferation and survival via its inhibitory effects on cellular
apoptosis.

Figure 2.

Model for involvement of caveolae in TGF-β signal transduction and

downregulation. Following ligand binding and receptor activation, activated TGF-β receptors
can be internalized through two distinct endocytic pathways. The non-lipid raft pathway (green)
results in increased TGF-β signal transduction, leading to tissue fibrosis and at the same time to
transcriptional downregulation of caveolin-1 (cav-1) gene expression. The decrease in caveolin-1
expression generates a vicious cycle that both increases and perpetuates tissue fibrosis. In
contrast, the caveolin-1 positive lipid raft compartment (red), drives TGF-β receptor proteasomal
degradation, leading to abrogation of the fibrotic response. Reproduced from Reference 51.
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